Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Discover Oncology · 20.09.2024 · 15 (1)
DOI: 10.1007/s12672-024-01349-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 20.09.2024. Verfasst von Anouchka Coste Holt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Holy Cross and University of Miami, Fort Lauderdale, FL, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Adding pembrolizumab to neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) improves pathologic complete response (pCR) rates and event-free survival. The impact of adding immunotherapy to NAC on surgical outcomes is unknown. This study compares 90-day post-surgical complications (PSCs) and time to adjuvant treatment among patients undergoing NAC for TNBC with and without immunotherapy.
Methods
Patients treated with NAC alone or with immunotherapy (NAC-I) for stage I–III TNBC between 2018 and 2022 were retrospectively identified at a single academic institution. Kruskal–Wallis rank sum and Fisher's exact tests compared patient sociodemographic and clinical characteristics. Multivariable logistic regression determined odds ratios (OR) predicting PSCs.
Results
Of 54 patients, 29 received NAC alone and 25 received NAC-I. Compared to NAC patients, NAC-I patients had more advanced stage tumors (p = 0.038), and had slightly higher rates of mastectomy with reconstruction (p = 0.193). 72.0% of NAC-I patients experienced a pCR, compared with 44.8% of NAC patients (p = 0.193). There were 10 PSCs (34.5%) in NAC patients compared to 9 PSCs (36.0%) in NAC-I patients (p > 0.99). Regression analysis demonstrated no association of PSCs with NAC-I (OR 0.83, 95% CI 0.19–3.60). Time to adjuvant therapy was shorter for NAC-I patients (28 days vs 36 days, p = 0.013).
Conclusions
Patients with TNBC receiving NAC-I have higher pCR rates and do not appear to have added 90-day PSCs or delays to adjuvant therapy despite trending toward more extensive surgical procedures compared to NAC alone. Larger studies are needed to further evaluate the surgical safety of immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Holy Cross and University of Miami, Fort Lauderdale, FL, USA.
- Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA.
- Division of Hematology and Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
- Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. nskapoor@mednet.ucla.edu.
Zitieren
APA
Holt, A. C., Smith, C. A., Berkowitz, M. J., Baker, J. L., McAndrew, N. P., & Kapoor, N. S. (2024). Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01349-7
Vancouver
Holt AC, Smith CA, Berkowitz MJ, Baker JL, McAndrew NP, Kapoor NS. Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01349-7
BibTeX
@article{Holt2024,
author = {Holt, Anouchka Coste and Smith, Courtney A and Berkowitz, Maurice J and Baker, Jennifer L and McAndrew, Nicholas P and Kapoor, Nimmi S},
title = {Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-01349-7}
}
EUVIMED